40
Participants
Start Date
June 30, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
August 31, 2009
EGP-437 1.6 mA-min at 0.4 with EyeGate® II System
Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System
Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System
Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
New York Eye & Ear Infirmary, New York
Pennsylvania College of Optometry, Elkins Park
Scheie Eye Institue, Philadelphia
Virginia Eye Consultants, Norfolk
Emory Eye Center, Atlanta
University of Miami, Miami
Southern College of Optometry, Memphis
Cleveland Eye Clinic, Cleveland
Comprehensive Eye Care Ltd., Washington
Texas Retina Associates, Dallas
Oregon Health Services University, Portland
Narayana Nethralaya, Bangalore
Kasturba Medical College and Hospital, Manipal
Christian Medical College, Vellore
Ophthalmic Consultants of Boston, Boston
Massachusetts Eye Research and Surgery Institution, Cambridge
St. Johns Medical College and Hospital, Bangalore
Vittala International Institute of Ophthalmology, Bangalore
M. M. Joshi Eye Institute, Hubli
Lead Sponsor
Eyegate Pharmaceuticals, Inc.
INDUSTRY